Loading…
Jenburkt Pharmaceuticals (JENBURPH)₹953.75−2.08%Pharmaceuticals
Jenburkt Pharmaceuticals is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 12.8 against a peer median of 26.7, and ROCE of 27.0% against a peer median of 12.0%, and latest-quarter sales growth of −0.2% against a peer median of 31.0%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Transchem | 509 | 119.3 | — | — | 0.00 | 0.0 | 0 | 4 | — | 204.5 | vs JENBURPH |
| Trident Lifeline | 505 | 22.3 | 21.0 | 22.6 | 0.73 | 0.1 | 129 | 19 | 50.4 | 29.5 | vs JENBURPH |
| KRM Ayurveda | 495 | 24.5 | 35.0 | 29.0 | 0.00 | 0.0 | 102 | 20 | 31.0 | 123.8 | vs JENBURPH |
| Albert David | 457 | 20.2 | 1.0 | −0.4 | 0.08 | 0.6 | 333 | −1 | 42.3 | 300.6 | vs JENBURPH |
| Infinium Pharmachem | 421 | 34.5 | 13.0 | 10.6 | 0.00 | 0.0 | 189 | 14 | 45.2 | 166.1 | vs JENBURPH |
| HALEOS LABS | 421 | 26.7 | 10.0 | 8.4 | 0.52 | 0.1 | 333 | 18 | −11.6 | −58.2 | vs JENBURPH |
| Jenburkt Pharmaceuticals | 420 | 12.8 | 27.0 | 20.2 | 0.01 | 2.2 | 169 | 35 | −0.2 | −24.4 | — |
| Jenburkt Pharmaceuticals | 417 | 12.7 | 27.0 | 20.3 | 0.01 | 1.9 | 169 | 35 | 0.0 | −24.4 | vs JENBURPH |
| Medicamen Biotech | 379 | 34.8 | 5.0 | 4.0 | 0.17 | 0.4 | 197 | 10 | 11.3 | 15.7 | vs JENBURPH |
| Astonea Labs | 352 | 77.5 | 11.0 | 11.9 | 0.75 | 0.0 | 148 | 5 | — | — | vs JENBURPH |
| Aarey Drugs & Pharmaceuticals | 337 | 66.9 | 6.0 | 2.8 | 0.33 | 0.0 | 474 | 4 | 75.4 | 237.0 | vs JENBURPH |
| Peer median | 421 | 26.7 | 12.0 | 11.3 | 0.08 | 0.1 | 169 | 14 | 31.0 | 76.7 |
Listed companies closest to Jenburkt Pharmaceuticals in Pharmaceuticals include Transchem, Trident Lifeline, KRM Ayurveda, Albert David, Infinium Pharmachem, HALEOS LABS, Jenburkt Pharmaceuticals, Medicamen Biotech.
Transchem, with a market cap of ₹509 Cr.
Jenburkt Pharmaceuticals trades at a P/E of 12.8; the median of its peer set is 26.7. A P/E above or below the median is a description, not a judgement on value.
Jenburkt Pharmaceuticals' return on capital employed is 27.0%, above the peer median of 12.0%.